130 related articles for article (PubMed ID: 38709961)
21. Examining Opportunities to Increase Savings From Medicare Price Negotiations.
Reitsma MB; Dusetzina SB; Ballreich JM; Trujillo AJ; Mello MM
JAMA Intern Med; 2023 Jun; 183(6):581-588. PubMed ID: 37067794
[TBL] [Abstract][Full Text] [Related]
22. An early look at changes in employer-sponsored insurance under the Affordable Care Act.
Blavin F; Shartzer A; Long SK; Holahan J
Health Aff (Millwood); 2015 Jan; 34(1):170-7. PubMed ID: 25527604
[TBL] [Abstract][Full Text] [Related]
23. Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans.
Yu T; Jin S; Li C; Chambers JD; Hlávka JP
BioDrugs; 2023 Jul; 37(4):531-540. PubMed ID: 37004706
[TBL] [Abstract][Full Text] [Related]
24. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
Shaw DL; Dhruva SS; Ross JS
J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
[TBL] [Abstract][Full Text] [Related]
25. Medicare Part D-a roundtable discussion of current issues and trends.
Balfour DC; Evans S; Januska J; Lee HY; Lewis SJ; Nolan SR; Noga M; Stemple C; Thapar K
J Manag Care Pharm; 2009; 15(1 Suppl A):3-9. PubMed ID: 19125555
[TBL] [Abstract][Full Text] [Related]
26. Association of Generic Competition With Price Decreases in Physician-Administered Drugs and Estimated Price Decreases for Biosimilar Competition.
Dickson SR; Kent T
JAMA Netw Open; 2021 Nov; 4(11):e2133451. PubMed ID: 34779844
[TBL] [Abstract][Full Text] [Related]
27. Strategies for Overcoming Barriers to Adopting Biosimilars and Achieving Goals of the Biologics Price Competition and Innovation Act: A Survey of Managed Care and Specialty Pharmacy Professionals.
Greene L; Singh RM; Carden MJ; Pardo CO; Lichtenstein GR
J Manag Care Spec Pharm; 2019 Aug; 25(8):904-912. PubMed ID: 31007119
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
29. The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program.
Bond AM; Dean EB; Desai SM
Health Aff (Millwood); 2023 May; 42(5):632-641. PubMed ID: 37126754
[TBL] [Abstract][Full Text] [Related]
30. Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D.
Yazdany J; Dudley RA; Lin GA; Chen R; Tseng CW
JAMA; 2018 Sep; 320(9):931-933. PubMed ID: 30193264
[TBL] [Abstract][Full Text] [Related]
31. Health care reform: managed competition and beyond.
Custer W
EBRI Issue Brief; 1993 Mar; (135):1-33. PubMed ID: 10129612
[TBL] [Abstract][Full Text] [Related]
32. Biosimilar Uptake in Medicare Part B Varied Across Hospital Outpatient Departments and Physician Practices: The Case of Filgrastim.
Socal MP; Anderson KE; Sen A; Bai G; Anderson GF
Value Health; 2020 Apr; 23(4):481-486. PubMed ID: 32327165
[TBL] [Abstract][Full Text] [Related]
33. The Medicare Catastrophic Coverage Act of 1988 and its impact on employer-sponsored retiree medical plans.
Melbinger MS; O'Donnell T
Employee Relat Law J; 1988-1989 Winter; 14(3):399-406. PubMed ID: 10303099
[TBL] [Abstract][Full Text] [Related]
34. Tax breaks for employer-sponsored health insurance.
Natl Bur Econ Res Bull Aging Health; 2010; (1):2-3. PubMed ID: 20568675
[No Abstract] [Full Text] [Related]
35. Medicare on life support: will it survive?
Fronstin P; Copeland C
EBRI Issue Brief; 1997 Sep; (189):1-22. PubMed ID: 10173777
[TBL] [Abstract][Full Text] [Related]
36. How does drug coverage vary by insurance type? Analysis of drug formularies in the United States.
Régnier SA
Am J Manag Care; 2014 Apr; 20(4):322-31. PubMed ID: 24884863
[TBL] [Abstract][Full Text] [Related]
37. Comparing patient OOP spending for specialty drugs in Medicare Part D and employer-sponsored insurance.
Parasrampuria S; Sen AP; Anderson GF
Am J Manag Care; 2020 Sep; 26(9):388-394. PubMed ID: 32930551
[TBL] [Abstract][Full Text] [Related]
38. Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019.
Liu A; Xuan A; Socal M; Anderson G; Anderson KE
J Manag Care Spec Pharm; 2024 Jan; 30(1):15-21. PubMed ID: 38153867
[TBL] [Abstract][Full Text] [Related]
39. Comparing employer-sponsored and federal exchange plans: wide variations in cost sharing for prescription drugs.
Buttorff C; Andersen MS; Riggs KR; Alexander GC
Health Aff (Millwood); 2015 Mar; 34(3):467-76. PubMed ID: 25732498
[TBL] [Abstract][Full Text] [Related]
40. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
